Biogen (BIIB) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$10.0B

Revenue (quarter)

$2.7B

Revenue growth (year over year)

+3.42%

Gross profit (trailing twelve months)

$7.4B

Gross margin

73.99%

Net income (trailing twelve months)

$834.6M

Net income (quarter)

$97.5M

Net income growth (year over year)

−84.64%

Net margin

8.32%

Return on equity

4.58%

EPS (trailing twelve months)

$5.68

Book value per share

$127.61

P/E (trailing twelve months)

42.26

Price to book

1.87

Debt to assets

41.26%

Payout ratio

—

Dividend yield

—

Company profile

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

• Is Biogen (BIIB) profitable?

  Yes. Biogen earned $834.6M in net income over the trailing twelve months, a net margin of 8.32%.

• How much revenue does Biogen (BIIB) make?

  Biogen generated $10.0B in revenue over the trailing twelve months, up 3.42% year over year.

• What is BIIB's P/E ratio?

  Biogen trades at 42.3 times trailing twelve-month earnings, on an EPS of $5.68.

• How do I buy stock in Biogen (BIIB)?

  BIIB trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.